

SUPPLEMENTARY MATERIALS

Table S1. The association of cardiac biomarkers with cardiovascular and all-cause mortality, excluding participants with hyperlipidemia and current smoking.

	Cardiovascular Mortality		All-Cause Mortality	
	HR (95% CI)	p	HR (95% CI)	p
No. of events	43		185	
hsTnT	4.84 (1.26, 18.46)	0.02	1.64 (1.28, 2.09)	0.0002
hsTnl (Abbott)	2.04 (1.41, 2.96)	0.0004	1.39 (1.14, 1.68)	0.002
hsTnl (Ortho)	1.52 (1.21, 1.92)	0.0007	1.00 (0.35, 2.85)	1.00
hsTnl (Siemens)	1.31 (0.84, 2.04)	0.22	1.20 (1.01, 1.44)	0.04
NT-proBNP	2.25 (1.16, 4.33)	0.02	1.23 (1.09, 1.39)	0.002

Modes adjusted for age, sex, race or ethnicity, insurance, former smoking, survey year, food insecurity, BMI, hemoglobin A1c, total cholesterol, systolic blood pressure, physical activity, use of ACEi/ARB, use of statin, eGFR

Table S2. The association of cardiac biomarkers with all-cause mortality among adults without subclinical CVD.

	Without Subclinical CVD		With Subclinical CVD	
	HR (95% CI)	p	HR (95% CI)	p
No. of events	303		138	
hsTnT				
Model 1	1.26 (0.93, 1.71)	0.13	1.39 (1.03, 1.86)	0.03
Model 2	1.17 (0.87, 1.58)	0.29	1.45 (1.05, 1.99)	0.02
Model 3	1.20 (0.88, 1.64)	0.25	1.47 (1.07, 2.02)	0.02
hsTnl (Abbott)				
Model 1	1.10 (0.89, 1.37)	0.37	1.70 (1.24, 2.32)	0.001
Model 2	1.08 (0.86, 1.35)	0.52	1.55 (1.12, 2.14)	0.009
Model 3	1.08 (0.86, 1.35)	0.50	1.55 (1.12, 2.14)	0.009
hsTnl (Ortho)				
Model 1	1.13 (0.97, 1.32)	0.11	1.84 (1.43, 2.37)	<0.0001
Model 2	1.13 (0.94, 1.37)	0.19	1.68 (1.30, 2.17)	0.0002
Model 3	1.13 (0.94, 1.36)	0.19	1.68 (1.30, 2.17)	0.0002
hsTnl (Siemens)				
Model 1	1.06 (0.92, 1.23)	0.42	1.22 (0.95, 1.56)	0.11
Model 2	1.05 (0.90, 1.21)	0.55	1.12 (0.87, 1.44)	0.37
Model 3	1.05 (0.90, 1.20)	0.54	1.12 (0.87, 1.44)	0.37
NT-proBNP				
Model 1	1.16 (1.01, 1.33)	0.04	1.34 (1.12, 1.61)	0.002
Model 2	1.13 (0.98, 1.30)	0.08	1.31 (1.06, 1.66)	0.03
Model 3	1.14 (0.99, 1.31)	0.08	1.31 (1.03, 1.67)	0.03

Model 1: adjusted for age, sex, race or ethnicity, insurance, smoking, survey year, food insecurity.

Model 2: adjusted for Model 2 + BMI, hemoglobin A1c, total cholesterol, systolic blood pressure, physical activity, use of ACEi/ARB, use of statin.

Model 3: adjusted for Model 3 + eGFR

Table S3. The association of subclinical CVD with cardiovascular and all-cause mortality.

	Cardiovascular Mortality		All-Cause Mortality	
	HR (95% CI)	p	HR (95% CI)	p
No. of events	83		441	
Subclinical CVD defined by hs-cTnT and NT-proBNP ^a				
Crude	6.75 (3.58, 12.73)	<0.0001	4.23 (2.37, 5.49)	<0.0001
Model 1	2.15 (1.03, 4.51)	0.04	1.87 (1.33, 1.62)	0.0006
Model 2	2.00 (0.82, 4.88)	0.13	1.62 (1.09, 2.42)	0.02
Model 3	1.97 (0.78, 4.97)	0.15	1.62 (1.08, 2.42)	0.02
Subclinical CVD defined by hs-cTnl (Abbott) ^b				
Crude	3.00 (0.36, 24.17)	0.30	2.57 (1.08, 6.12)	0.03
Model 1	2.37 (0.36, 15.76)	0.36	2.24 (1.17, 4.27)	0.02
Model 2	2.29 (0.27, 19.39)	0.44	1.81 (0.89, 3.69)	0.10
Model 3	2.27 (0.26, 19.70)	0.45	1.81 (0.88, 3.69)	0.10

Model 1: adjusted for age, sex, race or ethnicity, insurance, smoking status, survey year, food insecurity.

Model 2: adjusted for Model 2 + BMI, hemoglobin A1c, total cholesterol, systolic blood pressure, physical activity, use of ACEi/ARB, use of statin.

Model 3: adjusted for Model 3 + eGFR

^a Subclinical CVD defined by hs-cTnT \geq 22 ng/L among men or hs-cTnT \geq 14 ng/L among women or NT-proBNP $>$ 125 pg/mL.

^b Subclinical CVD defined by hs-cTnl (Abbott) \geq 12 ng/L among men and \geq 10 ng/L among women.